Annals of Oncology Advance Access originally published online on June 14, 2005
Annals of Oncology 2005 16(8):1366-1373; doi:10.1093/annonc/mdi259
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
1 Division of Hematology Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi 2 Division of Hematology, Department of Medicine, 3 Department of Pathology, 4 Division of Oncology, Department of Medicine and 5 Division of Transfusion Medicine, Department of Medicine, Taipai Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
* Correspondence to: Dr J.-P. Gau, Division of Hematology, Taipei Veterans General Hospital, and National Yang-Ming University School of Medicine, Taipei, Taiwan. Tel: +886-2-28712121, ext. 3866; Fax: +886-2-28757523; Email: jpgau{at}vghtpe.gov.tw
Background: Elderly patients with acute myeloid leukemia (AML) generally have an unfavorable clinical course and are under-represented in clinical trials. The aim of this study was to analyze the prognosis and treatment outcome of elderly AML patients.
Patients and methods: We studied 205 AML patients aged 65 years or older at our hospital. Prior to study initiation, we designated 13 variables to be analyzed for their impact on complete remission (CR) rate and overall survival (OS).
Results: Induction regimen (standard chemotherapy) and good performance status (PS) (Eastern Cooperative Oncology Group PS 0–1) independently influenced the achievement of CR. Multivariate analysis also determined five poor prognostic factors for OS: poor PS (score 2–4), presence of comorbidities, elevated serum lactate dehydrogenase level (
2x upper normal limit), extreme leukocytosis (100 x 109/l) and marked thrombocytopenia (
20 x 109/l). Age was not an independent contributing factor in terms of either CR attainment or OS duration. Low-risk patients, who possessed one or less non-leukocytosis poor prognostic factor, had significantly longer disease-free survival and OS than their high-risk counterparts.
Conclusions: Elderly AML patients should be risk-stratified at diagnosis. Anthracycline-based induction chemotherapy would be the best therapeutic option for such patients.
Key words: AML, elderly, prognosis, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard, D. Stockelberg, U. Tidefelt, A. Wahlin, and M. Hoglund Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood, April 30, 2009; 113(18): 4179 - 4187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y-B Yu, J-P Gau, J-Y You, H-H Chern, W-K Chau, C-H Tzeng, C-H Ho, and H-C Hsu Cost-effectiveness of postremission intensive therapy in patients with acute leukemia Ann. Onc., March 1, 2007; 18(3): 529 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palmieri, A. M. D'Arco, M. Celentano, G. Mele, C. Califano, F. Pollio, M. R. D'Amico, and F. Ferrara An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients Ann. Onc., July 1, 2006; 17(7): 1146 - 1151. [Abstract] [Full Text] [PDF]
|
|